{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-b/management/prevention-of-infection-with-hepatitis-b/","result":{"pageContext":{"chapter":{"id":"b2d949a2-a42f-5c0a-a955-414bac741bd3","slug":"prevention-of-infection-with-hepatitis-b","fullItemName":"Scenario: Prevention of infection with Hepatitis B","depth":2,"htmlHeader":"<!-- begin field bb3b8218-6608-4062-94bc-e8ebff37f8ae --><h2>Scenario: Prevention of infection with Hepatitis B</h2><!-- end field bb3b8218-6608-4062-94bc-e8ebff37f8ae -->","summary":"Covers the prevention of, and protection against, infection in people at high risk of hepatitis B.","htmlStringContent":"<!-- begin item 0e2a7eef-919b-48cc-9517-b11f032e5c68 --><!-- begin field 2293c0a5-d0db-4df2-b873-acbd0086438f --><p>From birth onwards.</p><!-- end field 2293c0a5-d0db-4df2-b873-acbd0086438f --><!-- end item 0e2a7eef-919b-48cc-9517-b11f032e5c68 -->","topic":{"id":"f75dcfde-3cb4-5059-94df-19d53a6c28e9","topicId":"4fc86266-0752-4667-994f-7f6fc7e46056","topicName":"Hepatitis B","slug":"hepatitis-b","lastRevised":"Last revised in November 2019","chapters":[{"id":"986057cd-07a1-565e-9c7a-d3b3dc88368d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2331f5c5-fb51-54d1-b722-946b4f34a693","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"653459fe-510a-5a1a-92dc-8197c598c85e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"12e8fb8c-9424-5f20-90e5-65e823f603c3","slug":"changes","fullItemName":"Changes"},{"id":"2299e2ba-3fb3-5f37-9c6b-63ec8dbbffd6","slug":"update","fullItemName":"Update"}]},{"id":"c14d3383-629b-5bd6-b6c0-318bbcf86fb2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58e5cd67-9ca7-5bfe-b2b6-bf4372ac895f","slug":"goals","fullItemName":"Goals"},{"id":"a1abbdfd-238b-55b7-8de2-09fd4ff6065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fc44420e-13ab-526e-a0c7-ef2f93cce77b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b59d4642-5914-585b-82b1-6f7989cef100","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"af246587-2615-513e-aafc-3ea762d8aab7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bba17b9f-47f8-52cf-a8e7-111c1a5094a2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c6fa000-50a2-5823-9acb-0bd808dc51e6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dfcb6ed4-783a-5fbc-9259-096762bb7c69","slug":"definition","fullItemName":"Definition"},{"id":"e06f78dc-080c-542f-b450-356db08c00a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c1d15cf-36ee-5c84-ad7c-e06836a161c0","slug":"transmission","fullItemName":"Transmission"},{"id":"939f1d6a-6b15-5c4f-91c8-9164e800cd87","slug":"people-at-high-risk-of-hepatitis-b","fullItemName":"People at high risk of hepatitis B"},{"id":"d452f04a-7d9d-5739-9cb9-f583eb136f3a","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b3642d36-7175-548b-b6f0-d694e7397bd3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6acbd5e1-b0e6-527b-bad0-42c21a928d1e","slug":"when-to-test-for-hepatitis-b","fullItemName":"When to test for hepatitis B"},{"id":"706362c9-e255-511b-83b4-74b853c926c7","slug":"how-to-test-for-hepatitis-b","fullItemName":"How to test for hepatitis B"},{"id":"c0c1ae56-2316-56eb-ad65-4b85e982fc11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"41c2681f-bf40-5b08-a518-32f2ab1206fb","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2d949a2-a42f-5c0a-a955-414bac741bd3","slug":"prevention-of-infection-with-hepatitis-b","fullItemName":"Scenario: Prevention of infection with Hepatitis B"},{"id":"00ed825c-5927-50f5-940d-94d6b4001150","slug":"managing-hepatitis-b-infection","fullItemName":"Scenario: Managing hepatitis B infection"}]},{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8df28bde-0bc5-533e-a54b-507fd3ceee61","slug":"hepatitis-b-vaccine","fullItemName":"Hepatitis B vaccine"},{"id":"c7099851-c102-56f2-b063-021f3d00b880","slug":"analgesics","fullItemName":"Analgesics"},{"id":"6a9675fd-5496-5ca4-9a76-36ee6cc93a25","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"1576eb24-e96c-50e6-9976-05164be1127e","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"3c7651c1-b246-51db-85b3-e1b6713a47bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"548463b9-9c49-5154-bad9-fe10668804da","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b3032fc-e20a-509b-b390-81cef2509ded","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5e0cdb38-e518-5a0c-9215-493c78f74377","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e63144c-a0f3-5eb1-980d-a219e8a53633","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"94d851c4-3314-5a3d-801a-0a208e287514","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4df2edc1-d17c-57d1-a914-4100299c8f7d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cecf6c0b-d134-54cb-abef-c2ccab9effb6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"41c2681f-bf40-5b08-a518-32f2ab1206fb","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0e716373-77b1-5290-9e1a-6193b75fdf0a","slug":"hepatitis-b-immunization","fullItemName":"Hepatitis B immunization","depth":3,"htmlHeader":"<!-- begin field 65fc5813-8ed5-4a91-8fa1-1a90ee38135f --><h3>Hepatitis B immunization for people at high risk</h3><!-- end field 65fc5813-8ed5-4a91-8fa1-1a90ee38135f -->","summary":null,"htmlStringContent":"<!-- begin item cc6a777d-a286-48a9-a991-9267bfcc74a9 --><!-- begin field dd61c457-e711-4405-9159-90c14941c693 --><p><strong>Offer hepatitis B immunization to <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-b/background-information/people-at-high-risk-of-hepatitis-b/\">people at high risk</a> of hepatitis B:</strong></p><ul><li><strong>Use clinical judgement (based on the person's risk of already having been exposed to hepatitis B) to determine the requirement for serology testing for immunity to hepatitis B at the same time as vaccination. People at high risk of previous exposure include:</strong><ul><li>Babies born to mothers infected with hepatitis B.</li><li>People with needlestick injury.</li><li>Sexual assault victims.</li><li>Injecting drug users.</li><li>People who change sexual partners frequently, particularly men who have sex with men, and sex workers.</li><li>Close family contacts of a person with hepatitis B.</li></ul></li><li><strong>For most people requiring pre- or post-exposure prophylaxis against hepatitis B, use a rapid immunization schedule</strong> (given at zero, one and two months, or over 21 days if very rapid protection is needed, such as for needlestick injuries or imminent travel to a highly endemic area). For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-b/prescribing-information/hepatitis-b-vaccine/#immunization-schedule\">immunization schedule</a>.<ul><li>For people where there is a high likelihood of compliance and rapid protection is not required, consider a three dose course of vaccine at zero, one and six months.</li><li>For information on the immunization schedule for babies born to women with hepatitis B, see Public Health England's information leaflet for Information for GPs and practice nurses <a data-hyperlink-id=\"e9838dea-9814-4e23-b949-ab07012d07df\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/736036/HepB_babies_aide_memoire_.pdf\">Hepatitis B vaccine for at risk infants</a>.</li><li>If immunity to hepatitis B is demonstrated following initial serology testing, do not give the remaining doses of vaccine.</li></ul></li><li><strong>Arrange for immunoglobulin prophylaxis to be given at the same time as vaccination </strong><strong>for people without proven hepatitis B immunity, following exposure to potentially infected blood or body fluids </strong>(including via needlestick, bite, or scratch injuries, contact with infected potentially material via mucous membranes [eyes or mouth], or broken skin, and unprotected sexual contact within last seven days with a person with hepatitis B).<ul><li>If immunoglobulin prophylaxis is thought to be indicated, discuss this with a microbiologist/the local health protection unit before giving treatment.</li><li>Hepatitis B immunoglobulin is given intramuscularly ideally within 48 hours of exposure, and at the same time as the first dose of vaccine.</li></ul></li><li>For detailed information on the hepatitis B vaccine, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-b/prescribing-information/hepatitis-b-vaccine/\">Prescribing Information</a>.</li></ul><!-- end field dd61c457-e711-4405-9159-90c14941c693 --><!-- end item cc6a777d-a286-48a9-a991-9267bfcc74a9 -->","subChapters":[{"id":"e24d6a91-73a2-5787-a2c0-46e5b3caa50f","slug":"fees-for-hepatitis-b-vaccination","fullItemName":"Fees for Hepatitis B vaccination","depth":4,"htmlHeader":"<!-- begin field 8e49cbb7-ee10-49d9-bef0-5b8b115e1646 --><h4>Fees for Hepatitis B vaccination</h4><!-- end field 8e49cbb7-ee10-49d9-bef0-5b8b115e1646 -->","summary":null,"htmlStringContent":"<!-- begin item 0f0e0639-6f57-4db4-a426-819280881704 --><!-- begin field 51574097-28f7-426c-ab6b-92e913e7c9d9 --><ul><li>Hepatitis B vaccine is not routinely available free of charge.</li><li>People requesting vaccination against hepatitis B in relation to travel abroad may be charged.</li><li>There is no charge if the vaccine is needed for treatment (for example, following a human bite) or to address a lifestyle-related risk (such as injected drug use).</li><li>Combination hepatitis A and B vaccines must be offered free of charge, but should only be used where protection against both illnesses is clinically indicated.</li><li>Where a person is at occupational risk of hepatitis B, it is the responsibility of their employer (or themselves if self-employed) to arrange and fund immunization.</li><li>For more detailed information, see the advice issued by the <a data-hyperlink-id=\"a837f695-9240-438d-b178-ab07010a8f44\" href=\"http://file///Users/JB/Downloads/Focus-on-hepatitis-B-immunisations-updated-Sept-2018.pdf\">General Practitioners Committee</a>.</li></ul><!-- end field 51574097-28f7-426c-ab6b-92e913e7c9d9 --><!-- end item 0f0e0639-6f57-4db4-a426-819280881704 -->","subChapters":[]},{"id":"a2814104-da20-58a1-baae-c38e802aeede","slug":"basis-for-recommendation-c61","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2eb03035-d4ea-488d-9b8e-0b6e52436730 --><h4>Basis for recommendation</h4><!-- end field 2eb03035-d4ea-488d-9b8e-0b6e52436730 -->","summary":null,"htmlStringContent":"<!-- begin item c618015f-9b52-4175-8d74-af7452a68474 --><!-- begin field 7eb79dfe-dcc9-4e74-99ae-d82a6c6d9e46 --><p>The information on immunization against hepatitis B is largely based on expert opinion in the British Association of Sexual Health and HIV (BASHH) <em>2017 interim update of the 2015 BASHH National Guidelines for the Management of the Viral Hepatitides </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">BASHH, 2017</a>], and the Public Health England (PHE) publication <em>Immunisation against infectious diseases</em> (the 'Green Book'), chapter 18, <em>Hepatitis B  </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2017</a>]<em>.</em></p><h5>Immunoglobulin prophylaxis</h5><ul><li>The information on the specific indications for immunoglobulin prophylaxis is based on expert opinion in the PHE document <em>Human hepatitis B immunoglobulin specific for hepatitis B post-exposure</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2019c</a>].</li></ul><h5>Fees</h5><ul><li>The information on the circumstances in which hepatitis B vaccination may incur a fee derives from the General Practitioners Committee document <em>Focus on hepatitis B immunisations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">General Practitioners Committee, 2018</a>].</li></ul><!-- end field 7eb79dfe-dcc9-4e74-99ae-d82a6c6d9e46 --><!-- end item c618015f-9b52-4175-8d74-af7452a68474 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}